Analysts Set Bausch + Lomb Co. (NYSE:BLCO) PT at $20.58

Bausch + Lomb Co. (NYSE:BLCO) has been given a consensus rating of “Hold” by the thirteen analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $20.58.

Several research firms recently commented on BLCO. Morgan Stanley lowered Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a research report on Monday, December 2nd. Citigroup cut Bausch + Lomb from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $22.00 in a report on Wednesday, December 11th. Royal Bank of Canada boosted their target price on Bausch + Lomb from $20.00 to $23.00 and gave the company an “outperform” rating in a research report on Tuesday, October 22nd. Stifel Nicolaus raised their price target on Bausch + Lomb from $16.00 to $19.00 and gave the stock a “hold” rating in a research report on Monday, September 23rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a research report on Thursday, October 31st.

Hedge Funds Weigh In On Bausch + Lomb

Hedge funds have recently added to or reduced their stakes in the stock. River Road Asset Management LLC grew its stake in Bausch + Lomb by 4.4% in the third quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company’s stock worth $38,974,000 after purchasing an additional 85,987 shares in the last quarter. Whitebox Advisors LLC lifted its holdings in shares of Bausch + Lomb by 28.2% in the 2nd quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company’s stock worth $22,447,000 after buying an additional 339,643 shares during the period. King Street Capital Management L.P. bought a new position in shares of Bausch + Lomb during the 3rd quarter worth $14,122,000. Clearline Capital LP increased its stake in shares of Bausch + Lomb by 136.8% during the second quarter. Clearline Capital LP now owns 712,055 shares of the company’s stock valued at $10,339,000 after buying an additional 411,404 shares during the period. Finally, Point72 Europe London LLP raised its holdings in shares of Bausch + Lomb by 28.9% in the second quarter. Point72 Europe London LLP now owns 653,492 shares of the company’s stock valued at $9,489,000 after acquiring an additional 146,583 shares in the last quarter. 11.07% of the stock is currently owned by institutional investors.

Bausch + Lomb Stock Down 1.3 %

Shares of BLCO opened at $17.85 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. The stock has a market capitalization of $6.29 billion, a price-to-earnings ratio of -17.00, a price-to-earnings-growth ratio of 1.74 and a beta of 0.47. Bausch + Lomb has a 1 year low of $13.16 and a 1 year high of $21.69. The business’s 50 day simple moving average is $19.03 and its 200-day simple moving average is $17.93.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.01. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the firm earned $0.22 earnings per share. Bausch + Lomb’s revenue was up 18.8% on a year-over-year basis. As a group, equities analysts expect that Bausch + Lomb will post 0.6 earnings per share for the current fiscal year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.